Seneca Biopharma Inc (CUR)
Neuralstem is a clinical stage biopharmaceutical company that is utilizing its proprietary human neural stem cell technology to create a platform of therapies for the treatment of central nervous system diseases. Co.'s technology platform has produced four key assets, two in clinical development and two in preclinical development: its NSI-566 stem cell therapy program (clinical stage) for treatment of paralysis, NSI-189 small molecule program (clinical stage) for Major Depressive Disorder and NSI-532 for Alzheimer's Disease and NSI-577 indicated for potential use in treatment of human demyelinating diseases, both of which are second-generation stem cell therapy programs (preclinical stage).
|
March 29, 2024 5:38 AM Eastern
Strong Buy (4.00 out of 4)
30th percentile
|
|